Literature DB >> 3937534

Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns.

G Franceschini, C R Sirtori, E Bosisio, V Gualandri, G B Orsini, A M Mogavero, A Capurso.   

Abstract

The plasma lipoprotein and apolipoprotein profile of 29 adult A-IMilano (A-IM) carriers and 29 age- and sex-matched non-affected subjects of the same kindred was examined, in order to investigate linkages between the lipid and apoprotein abnormalities and the phenotypic expression of the biochemical disorder. Carriers (A-IM+) showed a higher prevalence of hypertriglyceridemia (12 out of 29); they also had lower plasma total cholesterol, esterified cholesterol and phospholipids, compared to non-carriers. Lipoproteins were characterized by a significant enrichment of triglycerides in low and high density fractions (LDL and HDL), and by the expected striking reduction of HDL mass and cholesterolemia. Conversely, no significant alterations of the major circulating apolipoprotein levels, except for apo A-I and apo A-II, were noted in the A-IM+. The increased free cholesterol/esterified cholesterol ratio in plasma (most marked in HDL), was accompanied by a significant reduction of the lecithin cholesterol acyl transferase molar activity. Several correlations pertaining to lipids, lipoproteins and apoproteins were examined: cholesterol and triglycerides in HDL and, more remarkably, apoprotein A-I and C-III levels in plasma were significantly correlated in the A-IM+. While there was no significant prevalence of specific apo E phenotypes, plasma triglycerides and apo C-II levels were highly correlated in the carriers. The A-IM subjects, while in the presence of severe lipoprotein risk factors, may have alternative mechanisms of cholesterol disposal, potentially responsible for the apparently low prevalence of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3937534     DOI: 10.1016/0021-9150(85)90063-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  16 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 3.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

4.  Apolipoprotein A1 Baltimore (Arg10----Leu), a new ApoA1 variant.

Authors:  J A Ladias; P O Kwiterovich; H H Smith; S K Karathanasis; S E Antonarakis
Journal:  Hum Genet       Date:  1990-04       Impact factor: 4.132

Review 5.  Recombinant high-density lipoprotein formulations.

Authors:  Esad Vucic; Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

6.  Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.

Authors:  Herman J Kempen; Monica Gomaraschi; S Eralp Bellibas; Stephanie Plassmann; Brad Zerler; Heidi L Collins; Steven J Adelman; Laura Calabresi; Peter L J Wijngaard
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

7.  In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia.

Authors:  P Roma; R E Gregg; M S Meng; R Ronan; L A Zech; G Franceschini; C R Sirtori; H B Brewer
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 8.  Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases.

Authors:  Laura Calabresi; Cesare R Sirtori; Rodolfo Paoletti; Guido Franceschini
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

9.  Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I.

Authors:  Eric T Alexander; Masafumi Tanaka; Momoe Kono; Hiroyuki Saito; Daniel J Rader; Michael C Phillips
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

Review 10.  HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Authors:  Alan T Remaley; Marcelo Amar; Dmitri Sviridov
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.